Form 4: Guardant Health Co-CEO AmirAli Talasaz Sells Shares Under 10b5-1 Trading Plan

AmirAli Talasaz, Co-CEO of Guardant Health, sold shares of the company's common stock on May 1st and 2nd, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• AmirAli Talasaz, Co-Chief Executive Officer of Guardant Health, Inc., reported the sale of common stock on May 1st and 2nd, 2025.
• The sales were executed under a Rule 10b5-1 trading plan adopted on December 17, 2024.
• On May 1st, a total of 106,334 shares were sold at weighted average prices ranging from $47.6659 to $52.5729.
• On May 2nd, 13,932 shares were sold at a weighted average price of $50.4702.
• Following these transactions, Talasaz directly owns 2,188,740 shares of Guardant Health common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to insider trading. The sentiment is neutral as it simply reports transactions without expressing any opinion on the company's performance or future prospects.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 plan suggests the sales were pre-planned and not based on current inside information. Investors often monitor insider transactions for signals about a company's prospects, but sales under a 10b5-1 plan are generally viewed as less informative.

Comparison to Industry Standards

• It is common for executives at publicly traded companies, such as Guardant Health, to utilize 10b5-1 trading plans to sell shares.
• These plans allow insiders to diversify their holdings while avoiding concerns about trading on non-public information.
• The volume and frequency of sales are within the typical range observed for executives at similarly sized companies in the biotechnology sector.
• Comparable companies like Exact Sciences and Illumina also see regular insider trading activity, often through pre-arranged trading plans.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
• However, given the existence of a pre-arranged trading plan, the impact is likely to be minimal.

Key Dates

Keywords

Guardant Health, AmirAli Talasaz, stock sale, Form 4, Rule 10b5-1, insider trading